Announced
Completed
Financials
Sources
Tags
biopharmaceuticals
Pharmaceuticals
United States
Public
Completed
Friendly
Acquisition
Single Bidder
Majority
Cross Border
Synopsis
Shire, a specialty biopharmaceutical company, completed the acquisition of Baxalta, a biopharmaceutical company, for $32bn. "Upon the completion of our combination with Baxalta, Shire is now the global leader in rare diseases, with the number one rare diseases platform based on both revenue and pipeline programs. With our multiple high-value franchises, each with best-in-class products and a robust innovative portfolio, we further extend our capabilities for innovation and sustainable growth with patients at the center of everything we do," Flemming Ornskov, Shire CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.